
Certara, Inc. — Investor Relations & Filings
Certara, Inc. is a company that accelerates drug discovery and development through the use of proprietary biosimulation software, technology, and expert services. It provides an end-to-end platform that supports clients across the entire drug development lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's solutions leverage predictive simulation, data-driven modeling, and advanced analytics to help pharmaceutical and biotechnology organizations optimize trial design, justify dosing decisions, and navigate regulatory requirements. Key software products include Simcyp, Phoenix, and Pinnacle 21. Certara's offerings are designed to de-risk development, enhance efficiency, and increase the likelihood of bringing new medicines to patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | |
| ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | |
| 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | |
| 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 35223149 | 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | ||
| 33256151 | ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 33255090 | DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 32899219 | 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | ||
| 32899221 | 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 32899220 | 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 13319431 | Director's Dealing 2026 | 2026-01-12 | English | ||
|
2025
8 filings
| |||||
| 13319432 | FORM 8-K | 2025-12-11 | English | ||
| 13319433 | Major Shareholding Notification 2025 | 2025-11-25 | English | ||
| 13319434 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
| 13319435 | Director's Dealing 2025 | 2025-11-12 | English | ||
| 13319436 | 10-Q | 2025-11-06 | English | ||
| 13319437 | 8-K | 2025-11-06 | English | ||
| 13319438 | FORM 8-K | 2025-10-16 | English | ||
| 13319439 | Major Shareholding Notification 2025 | 2025-10-09 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ovation Science Inc.
Develops and licenses patented Invisicare® technology for e…
|
OVAT | CA | Professional, scientific and te… |
|
OXFORD BIODYNAMICS PLC
Develops and commercializes precision medicine tests for on…
|
OBD | GB | Professional, scientific and te… |
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
|
PACIFIC EDGE LIMITED
Develops non-invasive molecular tests for bladder cancer de…
|
PEB | NZ | Professional, scientific and te… |
|
PARADIGM BIOPHARMACEUTICALS LIMITED..
Repurposing PPS for osteoarthritis and rare inflammatory di…
|
PAR | AU | Professional, scientific and te… |
|
Pasithea Therapeutics Corp.
Develops treatments for central nervous system disorders, R…
|
KTTA | US | Professional, scientific and te… |
|
Passage BIO, Inc.
A clinical-stage genetic medicines company developing thera…
|
PASG | US | Professional, scientific and te… |
|
PATRYS LIMITED
Develops Deoxymab antibody therapies targeting DNA repair m…
|
PAB | AU | Professional, scientific and te… |
|
PAVmed Inc.
A diversified medical technology company developing devices…
|
PAVM | US | Professional, scientific and te… |
|
PegBio Co., Ltd.
Specializes in discovering and developing innovative therap…
|
2565 | HK | Professional, scientific and te… |
Certara, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31699/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31699 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31699 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31699 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31699}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Certara, Inc. (id: 31699)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.